Suppr超能文献

肝内胆管细胞癌肝转移:对更新分期系统的启示。

Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System.

机构信息

Medical Oncology/Institute of Cancer Sciences, The Christie NHS Foundation Trust/University of Manchester, Manchester, United Kingdom.

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.

出版信息

Hepatology. 2021 Jun;73(6):2311-2325. doi: 10.1002/hep.31598.

Abstract

BACKGROUND AND AIMS

Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread.

APPROACH AND RESULTS

Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I-III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan-Meier and Cox regression) was performed in an ENS-CCA training cohort (TC) and findings internally (ENS-CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS-CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS-CCA and SEER registries were reclassified into group C, respectively. In the ENS-CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18-5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS-CCA iVC (HR, 2.93; 95% CI, 2.04-4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68-2.09; P < 0.001).

CONCLUSIONS

iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including "liver metastases: multiple liver lesions, with or without vascular invasion" as an "M1a stage," is suggested.

摘要

背景与目的

肝内胆管细胞癌(iCCA)伴肝转移被认为预后不良,但美国癌症联合委员会(AJCC)在缺乏淋巴结或肝外转移的情况下将其归类为早期。

方法和结果

来自欧洲胆管癌研究网络(ENS-CCA)和监测、流行病学和最终结果(SEER)登记处的具有生存/分期(AJCC v.7)数据的 iCCA 患者符合条件。使用改良分期(mAJCC v.7):A 组:I-III 期(不包括 T2bN0);B 组:IVA 期(不包括 T2bN1M0);C 组:肝转移(T2bN0/1);D 组:IVB 期(肝外转移)。在 ENS-CCA 培训队列(TC)中进行生存分析(Kaplan-Meier 和 Cox 回归),并在内部(ENS-CCA iVC)和外部(SEER)验证发现。目的是评估肝转移(C 组)是否比其他早期阶段(A 组)的生存率更短,以提出 AJCC v.8 的改良版本(mAJCC v.8)。ENS-CCA 和 SEER 登记处共纳入 574 例和 4171 例患者。根据新分类,ENS-CCA 和 SEER 登记处分别有 19.86%和 17.31%的患者重新分类为 C 组。在 ENS-CCA TC 中,多变量 Cox 回归调整了肥胖(p=0.026)和表现状态(P<0.001);C 组患者(HR,2.53;95%CI,1.18-5.42;P=0.017)死亡风险更高(与 A 组相比)。ENS-CCA iVC(HR,2.93;95%CI,2.04-4.19;P<0.001)和 SEER 登记处(HR,1.88;95%CI,1.68-2.09;P<0.001)的验证结果一致。

结论

肝内胆管细胞癌伴肝转移的预后比其他早期肝内胆管细胞癌差。由于 AJCC v.8 没有考虑到这一点,建议对 AJCC v.8 进行修改(mAJCC v.8),包括“肝转移:多个肝内病变,伴或不伴血管侵犯”作为“M1a 期”。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7aa7/8252018/2a4221135c5d/HEP-73-2311-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验